Article

Adenoviral vectors for improved gene delivery to the inner ear.

Department of Otolaryngology, University of Heidelberg, Germany.
Hearing research (Impact Factor: 2.18). 01/2009; 248(1-2):31-8. DOI: 10.1016/j.heares.2008.11.009
Source: PubMed

ABSTRACT An important requirement for gene therapy in the inner ear is to achieve efficient gene delivery without damaging residual inner ear function. This can be achieved by delivering a high concentration of vector in a minimal volume. Adenovectors are well suited to meet these requirements since high quality concentrated vector with a high capacity for a gene payload can be produced. To reduce the number of vector particles and volume of delivery to the inner ear, we tested vectors with enhancements in cell binding and cell entry properties. We compared delivery of a marker gene to the inner ear using two different advanced generation serotype 5 adenovector designs. The first adenovector tested, AdRGD, has a restricted tropism of entry into cells. AdRGD is an Ad5 capsid vector with an arg-gly-asp (RGD) motif built into the adenovector fiber that has also been modified to abolish the fiber-CAR and penton-integrin interactions that provide the normal well characterized two-step entry pathway for adenovirus. The AdRGD vector has enhanced binding to alphanu integrins. The second vector, AdF2K, contains 7 lysine residues within the fiber knob and has been shown to have expanded tropism for cells in vitro and in vivo. AdF2K maintains its normal CAR and integrin receptors interactions and has an additional mechanism of entry via its ability to interact with heparan sulfate. Both vectors demonstrated effective delivery to the inner ear and more uniform labeling of the inner ear sensory epithelia than native capsid vector, when tested in vivo. Analysis of expression efficiency using quantitative PCR was tested in vitro on cultured macular organs and demonstrated that vector delivery with the AdF2K vector design yielded optimal delivery. The present study demonstrates that retargeting strategies can improve delivery to the inner ear.

0 Bookmarks
 · 
98 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Recent advances in human genomics led to the identification of numerous defective genes causing deafness, which represent novel putative therapeutic targets. Future gene-based treatment of deafness resulting from genetic or acquired sensorineural hearing loss may include strategies ranging from gene therapy to antisense delivery. For successful development of gene therapies, a minimal requirement involves the engineering of appropriate gene carrier systems. Transfer of exogenous genetic material into the mammalian inner ear using viral or non-viral vectors has been characterized over the last decade. The nature of inner ear cells targeted, as well as the transgene expression level and duration, are highly dependent on the vector type, the route of administration and the strength of the promoter driving expression. This review summarizes and discusses recent advances in inner ear gene-transfer technologies aimed at examining gene function or identifying new treatment for inner ear disorders.Gene Therapy advance online publication, 28 June 2012; doi:10.1038/gt.2012.51.
    Gene therapy 06/2012; · 4.75 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: This review highlights recent advances in cochlear gene therapy over the past several years. Cochlear gene therapy has undergone tremendous advances over the past decade. Beginning with some groundbreaking work in 2005 documenting hair cell regeneration using virally mediated delivery of the mouse atonal 1 gene, gene therapy is now being explored as a possible treatment for a variety of causes of hearing loss. Recent advances in cochlear gene therapy include improved methods of gene delivery with a better delineation of viral vectors that are suitable for this purpose, additional improvements in hair cell regeneration, and directed research toward autoimmune hearing loss, ototoxicity, spiral ganglion survival, and genetic forms of hearing loss. If successful, cochlear gene therapy will dramatically alter our ability to treat a variety of forms of acquired and genetic hearing loss.
    Current opinion in neurology 12/2011; 25(1):57-60. · 5.43 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: PURPOSE: The purposes of the current study were to assess the feasibility of post-auricular microinjection of lentiviruses carrying enhanced green fluorescent protein (EGFP) into the scala media through cochleostomies in rats, determine the expression of viral gene in the cochlea, and record the post-operative changes in the number and auditory function of cochlear hair cells (HCs). METHODS: Healthy rats were randomly divided into two groups. The left ears of the animals in group I were injected with lentivirus carrying EGFP (n=10) via scala media lateral wall cochleostomies, and the left ears of the animals in group II were similarly injected with artificial endolymph (n=10). Prior to and 30days post-injection, auditory function was assessed with click-auditory brainstem response (ABR) testing, EGFP expression was determined with cochlear frozen sections under fluorescence microscopy, and survival of HCs was estimated based on whole mount preparations. RESULTS: Thirty days after surgery, click-ABR testing revealed that there were significant differences in the auditory function, EGFP expression, and survival of HCs in the left ears before and after surgery in the same rats from each group. In group I, EGFP was noted in the strial marginal cells of the scala media, the organ of Corti, spiral nerves, and spiral ganglion cells. CONCLUSION: Lentiviruses were successfully introduced into the scala media through cochleostomies in rats, and the EGFP reporter gene was efficiently expressed in the organ of Corti, spiral nerves, and spiral ganglion cells.
    American journal of otolaryngology 03/2013; · 0.77 Impact Factor

Full-text

View
0 Downloads
Available from